For the first time in a clinical study, a drug has shown promise in reversing the damage incurred from the neurodegenerative disease, Multiple sclerosis (MS). A study involving patients who have been diagnosed with MS and suffer from stable chronic optic neuropathy was conducted. Researchers were testing the affects of an antihistamine drug called clemastine fumarate. While taking the drug, delays in how long it takes for the eyes to see something and pass it along to brain were reduced by an average of slightly less than two milliseconds in each eye per patient. “While the improvement in vision appears modest, this study is promising because it is the first time a drug has been shown to possibly reverse the damage done by MS,” said Green. “Findings are preliminary, but this study provides a framework for future MS repair studies and will hopefully herald discoveries that will enhances the brain’s innate capacity for repair.” To read more about their findings, click here.
